Cancer Res Treat.  2017 Jul;49(3):607-615. 10.4143/crt.2016.139.

Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea

• Joung JY
• Lim J
• Oh CM
• Jung KW
• Cho H
• Kim SH
• Seo HK
• Park WS
• Chung J
• Lee KH
• Won YJ

• KMID: 2388306
• DOI: http://doi.org/10.4143/crt.2016.139

Abstract

PURPOSE
This descriptive study assessed the current trends in the incidence of urological cancers and patient survival in Korea.
MATERIALS AND METHODS
In this nationwide retrospective observational study based on the data from the Korea National Cancer Incidence Database (KNCIDB), this study analyzed the age-standardized incidence rates (ASRs) and annual percentage changes (APCs) of kidney, bladder, prostate, testicular, and penile cancers as well as cancer of the renal pelvis and ureter between 1999 and 2012. The relative survival rates (RSRs) were calculated for urological cancer patients diagnosed between 1993 and 2012 from the KNCIDB data.
RESULTS
Prostate cancer was diagnosed in 66,812 individuals followed by bladder (41,549) and kidney (36,836) cancers. The overall ASR (18.26 per 100,000) increased with age because of the higher ASRs of bladder and prostate cancers in the elderly. The ASR for kidney cancer was highest in the 40-59-year-old group, whereas testicular cancer occurred most frequently before the age of 40. The incidence of most urological cancers increased (overall APC, 6.39%; p < 0.001), except for penile (APC, -2.01%; p=0.05) and bladder (APC, -0.40%; p=0.25) cancers. The overall survival increased steadily (5-year RSR, 66.4% in 1993-1995 vs. 84.2% in 2008-2012; p < 0.001), particularly for prostate (by 34.10%) and kidney (by 16.30%) cancers, but not for renal pelvis and ureter cancers (-7.20%).
CONCLUSION
The most common urological cancer in Korea was prostate cancer followed by bladder and kidney cancers. The incidence of most urological cancers, except for penile and bladder cancers, increased. Survival also increased, particularly for prostate and kidney cancers.

Keyword

Urologic neoplasms; Incidence; Survival; Korea

MeSH Terms

Aged
Humans
Incidence*
Kidney
Kidney Neoplasms
Kidney Pelvis
Korea*
Male
Observational Study
Penile Neoplasms
Prostate
Prostatic Neoplasms
Retrospective Studies
Survival Rate*
Testicular Neoplasms
Ureter
Ureteral Neoplasms
Urinary Bladder
Urinary Bladder Neoplasms
Urologic Neoplasms*

Figure

• 

  Fig. 1. The change of age-standardized incidence rate (ASR) of urologic cancer per 100,000 populations, 1999-2012. (A) Both. (B) Male. (C) Female.

• 

  Fig. 2. Annual percentage change (APC) of urologic cancer by sex in Korea, 1999-2012.

Reference

References

1. Shin HR. Global activity of cancer registries and cancer control and cancer incidence statistics in Korea. J Prev Med Public Health. 2008; 41:84–91.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108.

3. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47:127–41.

4. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. All cancers (excluding nonmelanoma skin cancer) estimated incidence, mortality and prevalence worldwide in 2012 [Internet]. Geneva: World Health Organization;2016. [cited 2016 Mar 1]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx#.

5. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006; 66:1285–91.

6. Cheon J, Kim CS, Lee ES, Hong SJ, Cho YH, Shin EC, et al. Survey of incidence of urological cancer in South Korea: a 15-year summary. Int J Urol. 2002; 9:445–54.

7. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization;2000.

8. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization;1994.

9. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–31.

10. Song W, Jeon HG. Incidence of kidney, bladder, and prostate cancers in Korea: an update. Korean J Urol. 2015; 56:422–8.

11. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010; 100:693–701.

12. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CG, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993; 85:1571–9.

13. Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. Jpn J Clin Oncol. 2015; 45:390–401.

14. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104:125–32.

15. Choi SK, Song C, Shim M, Min GE, Park J, Jeong IG, et al. Prevalence of high-grade or insignificant prostate cancer in Korean men with prostate-specific antigen levels of 3.0-4.0 ng/mL. Urology. 2015; 85:610–5.

16. Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, et al. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy. Urol Oncol. 2016; 34:3.

17. Morrison AS, Buring JE, Verhoek WG, Aoki K, Leck I, Ohno Y, et al. An international study of smoking and bladder cancer. J Urol. 1984; 131:650–4.

18. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7:245–57.

19. King SC, Pollack LA, Li J, King JB, Master VA. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol. 2014; 191:1665–70.

20. Adams KF, Leitzmann MF, Albanes D, Kipnis V, Moore SC, Schatzkin A, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol. 2008; 168:268–77.

21. Park HS, Park CY, Oh SW, Yoo HJ. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev. 2008; 9:104–7.

22. Pike MC, Chilvers CE, Bobrow LG. Classification of testicular cancer in incidence and mortality statistics. Br J Cancer. 1987; 56:83–5.

23. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009; 27:141–50.

24. Larke NL, Thomas SL, dos Santos Silva I, Weiss HA. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control. 2011; 22:1097–110.

25. Minhas S, Manseck A, Watya S, Hegarty PK. Penile cancer--prevention and premalignant conditions. Urology. 2010; 76(2 Suppl 1):S24–35.